the elephant is still in the room

andrew: You're mention that Janssen's renewal is the positive, touches on what I see as 'the elephant in the room'.

Of Phylogica's four pharma deals, the most important and valuable collaboration to Phylogica's success is the current Janssen deal, in the cell-penetrating peptide(drug conjugate)space.

From all reports this work has been progressing well, and scientists from both companies have been communicating via telcos as regularly as fortnightly. There is a close working relationship.

By building the next generation libraries of drug conjugates, Phylogica hope to position themselves as Janssen's preferred partner or an acquistion. If the endocytotic and endosomal escape capabilities are validated in the coming months Phylogica will finally have created something very valuable to big pharma and in-particular Janssen(Johnson & Johnson).
SoT